Shruti Wadhwa

Dr. Shruti Wadhwa

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
LDL. N. Dorairajan
L. N. Dorairajan
AHA. K. Hemal
A. K. Hemal
NGN. P. Gupta
N. P. Gupta
SWShruti Wadhwa
Shruti Wadhwa

24 November 1998 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
RKR. Kataria
R. Kataria
VBV. Bhatnagar
V. Bhatnagar
SWShruti Wadhwa
Shruti Wadhwa
DMD. K. Mitra
D. K. Mitra

1 July 1999 in Journal of Endourology
Verified
Journal Article
Closed access
AHA.K. Hemal
A.K. Hemal
MTManoj Talwar
Manoj Talwar
SWShruti Wadhwa
Shruti Wadhwa
NGN.P. Gupta
N.P. Gupta
Purpose: To describe, define, and evaluate the efficacy of retroperitoneoscopic nephrectomy (RPN) for benign diseases of the kidney and to compare it with open surgical nephrectomy (OSN) via a flank approach. Patients and Methods: From August 1995 to November 1997, 29 men and 14 women (mean age 33 years) with severely damaged kidneys underwent RPN. Among these, 11 patients had undergone prior surgery, 3 had chronic renal failure, and 8 patients had a percutaneous nephrostomy. The RPN was performed via three or four ports, with the kidneys being removed intact from the retroperitoneal working space. During the same period, 43 patients underwent OSN through a flank approach (extrapleural and extraperitoneal) for nonfunctioning or poorly functioning kidneys. Results: In the RPN group, two patients required conversion to OSN. The operative time and estimated blood loss ranged from 40 to 210 minutes (mean 114 minutes) and 50 to 450 niL (mean 127 mL). respectively. In the OSN group, the corresponding v...

1 May 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
JNJanki Rani Naidugari
Janki Rani Naidugari
SWShruti Wadhwa
Shruti Wadhwa
BXBenjamin Wenyuan Xie
Benjamin Wenyuan Xie
STSarah Marie Taheri
Sarah Marie Taheri
IKIndraneel Kulkarni
Indraneel Kulkarni
RRRebecca Redman
Rebecca Redman
Background: Macrophage migration inhibitory factor (MIF) is a critical modulator of the tumor immune microenvironment (TME). Its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains controversial because of HPV-dependent tumor biology and the limitations of single-timepoint biomarker assessments. This preliminary study evaluates whether dynamic changes in circulating MIF (ΔMIF) in an HPV-stratified longitudinal cohort reflect disease severity and treatment response. Methods: Ninety-six serial serum samples were analyzed from 27 HNSCC patients (22 HPV-positive, 5 HPV-negative) from diagnosis through therapy and follow-up. Serum MIF and anti-HPV16 E7 IgG were quantified by ELISA, and ΔMIF was defined as the change in MIF concentration between consecutive visits. Results: Baseline MIF did not correlate with clinical stage in the total cohort (p = 0.63). However, 56% of HPV-positive patients exhibited a positive correlation between elevated MIF and advanced stage. Following chemoradiotherapy, the HPV-negative group showed a consistent and significant decline in MIF (mean ΔMIF = −1.23, p = 0.031), corresponding with no evidence of disease (NED). In contrast, the HPV-positive group showed heterogeneous trajectories (mean ΔMIF = +0.21, p = 0.94), with several patients demonstrating paradoxical declines in MIF during active disease or relapse, followed by recovery upon reaching NED. In select cases, MIF dynamics were closely synchronized with anti-E7 IgG levels. Conclusions: Serum MIF dynamics are strongly dependent on HPV status. While MIF serves as a reliable therapy-monitoring marker in HPV-negative HNSCC, it may play a complex and paradoxical immunomodulatory role in HPV-positive disease. These preliminary findings support the need for larger prospective, HPV-stratified trials.

25 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JNJanki Rani Naidugari
Janki Rani Naidugari
SWShruti Wadhwa
Shruti Wadhwa
BXBenjamin Wenyuan Xie
Benjamin Wenyuan Xie
STSarah Marie Taheri
Sarah Marie Taheri
IKIndraneel Kulkarni
Indraneel Kulkarni
RRRebecca Redman
Rebecca Redman
Background: Macrophage migration inhibitory factor (MIF) shapes the tumor immune microen-vironment and has been implicated in head and neck squamous cell carcinoma (HNSCC), but its behavior may differ by HPV status. We evaluated whether dynamic changes in circulating MIF (ΔMIF) track disease severity and treatment response in HPV-positive (+) versus HPV-negative (-) HNSCC. Methods: In this single-center cohort study (n=27, 96 serial serum samples), clinical data were collected from diagnosis through therapy, remission, and relapse. MIF was quantified by ELISA and HPV status was assigned using p16 IHC, HPV DNA, and/or anti-E7 IgG. Associations with stage, treatment. and outcomes were analyzed using non-parametric/Fisher’s exact tests where appropriate. Results: At baseline (all patients), MIF did not correlate with clinical stage (p=0.63). Stratified analyses revealed heterogeneity: in HPV(+) patients (n=18 analyzable), 56% showed a direct cor-relation between high MIF levels and advanced stage disease, whereas HPV(−) patients (n=5) largely did not. Following concurrent cisplatin/radiation, HPV(−) patients demonstrated a consistent post-treatment decline in MIF (mean ΔMIF −1.23; p=0.031) and all achieved “no evidence of disease” status without recurrence. In contrast, HPV(+) patients showed mixed post-treatment MIF trajec-tories (mean ΔMIF +0.21; p=0.94). Over the full disease course, ΔMIF differed by HPV status (HPV(+) mean of +0.06 vs HPV(-) mean of −1.62; p=0.009. Conclusions: In HPV(-) HNSCC, post-treatment MIF decline strongly associates with effective response and remission, supporting MIF as a therapy-monitoring biomarker. In HPV(+) disease, baseline MIF may reflect severity, but post-treatment trajectories are heterogeneous and can decrease during active disease/relapse.

Verified
Journal Article
Open access
PDF file
TGTanya Gupta
Tanya Gupta
BSBenjamin Setters
Benjamin Setters
LHLama Hanbali
Lama Hanbali
SWShruti Wadhwa
Shruti Wadhwa
MDMichael Wesley Daniels
Michael Wesley Daniels
AVAditya Verma
Aditya Verma
Background: Faricimab is one of the most potent anti-vascular endothelial growth factors used in the management of diabetic macular edema (DME). However, real-world benefits regarding its timing and efficacy are still being explored. Methods: This retrospective non-randomized pilot study aimed to evaluate the efficacy of intravitreal faricimab in the treatment of DME. Eyes initially treatment-naïve for DME with a follow-up of 1 year were grouped as: group 1, where faricimab was introduced within the first six months after the start of treatment; group 2, where it was initiated six or more months after treatment with other drugs. Study parameters included changes in best corrected visual acuity (BCVA) and optical coherence tomography based structural parameters within the 6 × 6 mm optical coherence tomography (OCT) scan regions. Results: Forty-two eyes from 26 patients were analyzed. No statistically significant differences were observed between the groups in cluster-weighted proportions of intra- or sub-retinal fluid, retinal thickness or volume parameters, although group 1 showed modest numerical benefits. SRF showed a trend towards qualitative reduction in group 1, although IRF showed persistence in both groups. Adjusted linear mixed-effects modeling demonstrated no significant impact of early faricimab initiation on functional and anatomical outcomes, which appeared to be influenced by the baseline BCVA, glycemic control, and the number of injections, nullifying the benefits. Conclusions: Faricimab demonstrated modest anatomical improvements with earlier treatment in eyes initially treatment-naïve for DME. Further prospective studies are indicated to assess the treatment strategy and the timing of introduction with faricimab in such eyes.